Compare CALC & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALC | BHST |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | Canada |
| Employees | 16 | 87 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 97.7M |
| IPO Year | 2020 | N/A |
| Metric | CALC | BHST |
|---|---|---|
| Price | $0.64 | $4.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $10.00 | $10.00 |
| AVG Volume (30 Days) | ★ 241.0K | 27.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.27 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $4.10 |
| 52 Week High | $7.20 | $12.80 |
| Indicator | CALC | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 45.37 |
| Support Level | $0.50 | $4.27 |
| Resistance Level | $0.79 | $5.02 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 56.60 | 16.67 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.